Program Leaders

项目负责人

基本信息

批准号：
8250405
负责人：
HOWARD H. BAILEY
金额：
$ 23.3万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-04-01 至 2013-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8250405
关键词：
Action Potentials Address Androgen Receptor Animal Model Antineoplastic Agents Area Award Basic Science Biochemistry Cancer Center Cancer Control Cancer Etiology Cancer Patient Cancer Vaccines Cell model Chemistry Chemoprevention Chemopreventive Agent Chicago Chronic Clinical Clinical Investigator Clinical Research Clinical Trials Collaborations Complex Comprehensive Cancer Center Data Data Set Development Doctor of Philosophy Drug Metabolic Detoxication Education Educational workshop Enzymes Etiology Faculty Fellowship Fostering Fred Hutchinson Cancer Research Center Genes Genetic Genetic Programming Genomics Goals Group Meetings Human Human Genetics Immune response Immunologics Immunology India Inflammation Inflammatory Informatics Internal Medicine Laboratories Laboratory Study Lead Leadership Lymphocyte Malignant neoplasm of prostate Mammalian Genetics Maps Medical Medical Oncology Medicine Metabolic Activation Methods Molecular Biology Music Pathway interactions Patients Physicians Positioning Attribute Prostate Proteins Recording of previous events Research Research Activity Resource Sharing Rest Risk Role Scientist Therapeutic Tissues Training Translating Translational Research United States National Institutes of Health Universities Vaccine Adjuvant Vaccines Washington Wisconsin Work cancer cell cancer chemoprevention cancer genetics cancer genomics cancer prevention cancer risk carcinogenesis career college comparative diet and cancer genome sequencing genome-wide instrumentation interest malignant breast neoplasm medical schools member novel strategies post-doctoral training prevent professor programs prostatic fraction Acid phosphatase isoenzyme prostatitis residence treatment strategy

项目摘要

Several changes in the Leadership of UWCCC Programs will strengthen their translational potential. Dr. Michael Gould has assumed the role of Program Leader for Cancer Genetics. Dr. Gould received his Ph.D. from the University of Wisconsin followed by a postdoctoral fellowship at Argonne National Laboratory. He joined the faculty of the UWCCC in 1978 and has worked extensively throughout his career to integrate basic laboratory studies in breast cancer etiology and chemoprevention, including both basic and translational projects. Using animal models, he is searching for genes that prevent breast cancer. Once identified, these genes will provide a better understanding of the role of modifier genes and cancer risk and also provide targets for the development of anticancer drugs. He has previously served in many positions in the Cancer Center, including leadership of a breast cancer program and most recently leader of the Etiology and Chemoprevention Program. His current personal research interests as well as his history of fostering collaborations for translational research make him an ideal candidate to assume leadership of this program. As leader of this Program Dr. Gould is reorganizing the emphasis to include three areas. The first is mammalian and human genetics. The central goal of this area is using comparative genetics and genomics to better understand the etiology of cancer and its progression. This work is translated to humans in the form of risk estimation and cancer prevention. The second area is that of statistical genetics and informatics. Developing new statistical and informatic approaches to map the sequenced genomes will be a major focus as well as developing unique methods of analysis for complex data sets. The third area is physical genomics which will develop novel approaches for the acquisition of cancer genomics data on a genome wide scale. Dr. Gould facilitates Program interactions by organizing small group meetings that are task oriented as well as a limited number of large group meetings and retreats that provide education and the opportunity to explore potential collaborative strategies. He also facilitates educational workshops that introduce Program members to new UWCCC shared resources and instrumentation. He will foster the established important collaborative ties between the members Genetics Program, the Chemoprevention Program and the Cancer Control Program to facilitate translational inte-rprogrammatic research. Dr. Gould devotes 10% effort to leadership for this Program. Dr. Hasam Mukhtar has assumed the role of co-leader for the Chemoprevention Program. He received his PhD in Biochemistry from Kanpur University in Kanpur India in 1971. He did postdoctoral training at the Medical College of Georgia where his interest in detoxification enzymes was stimulated. After pursuing further work in this field at NIH, he became a faculty member at Case Western Reserve University and combined the expertise of metabolic activation and detoxification to explore ways to regulate carcinogenesis. His work has now extended to the study of diet and cancer and a focus on dietary substances for cancer chemoprevention. As co-leader of the Chemoprevention Program, Dr. Mukhtar will lead and stimulate the efforts to identify compounds with chemopreventive efficacy, foster the collaborations with translational scientists to identify mechanisms of action and potential targets, and initiate collaborations with physicians to explore options for treatment strategies for chemoprevention. He will devote 5% effort to this activity. Dr. Douglas McNeel will replace Dr. James Stewart as co-leader of the Experimental Therapeutics Program. Dr. McNeel joined the faculty at the University of Wisconsin as an Assistant Professor in the Department of Medicine in July 2001. He received his BA in Chemistry and Music at Whitman College in 1986. He then pursued graduate training under a Medical Scientist Training Award at the University of Chicago, and received his PhD (Biochemistry and Molecular Biology) in 1992 and MD in 1994. He then completed an Internal Medicine residence at the University of Washington on a Clinical Investigator Pathway, and a Medical Oncology fellowship at the University of Washington and Fred Hutchinson Cancer Research Center in 2000. After his clinical fellowship, he joined the Tumor Vaccine Group at the University of Washington for four years. At the University of Wisconsin, Dr. McNeel continues to focus on the immunology of prostate cancer. Laboratory studies seek to identify proteins expressed by prostate tissue that are recognized by lymphocytes in patients with prostate cancer and chronic inflammatory prostatitis, as well as identify vaccine strategies capable of inducing prostate-specific inflammation. Clinical studies explore whether immune responses capable of destroying prostate cancer cells can be elicited in patients with prostate cancer by means of vaccines. The long-range goal of this research is to develop vaccines for the adjuvant treatment of prostate cancer. Dr. McNeel was selected to co-lead this program to address an apparent lack of integration of program members who were employing immunologic therapeutic approached with the rest of the program. His clinical and research activities focus on prostate cancer and the use of immunological approaches, especially vaccines, for the treatment of prostate cancer. His laboratory is developing vaccines using cellular and animal models targeting prostatic acid phosphatase and androgen receptor. He also is leading clinical trials to evaluate these approaches in prostate cancer patients. Dr. McNeel will bring his considerable basic science and clinical expertise to the Experimental Therapeutics program and help to integrate the important immunological strengths of the program. He will devote 5% effort to this activity.

UWCCC计划领导的几个变化将增强其转化潜力。迈克尔·古尔德（Michael Gould）博士扮演了癌症遗传学计划负责人的角色。古尔德博士收到了他的博士来自威斯康星大学，随后在Argonne National Laboratory进行博士后研究金。他于1978年加入UWCCC的教职乳腺癌病因和化学预防的基础实验室研究，包括基本和翻译项目。使用动物模型，他正在寻找预防乳腺癌的基因。一旦确定，这些基因将更好地了解修饰剂基因和癌症风险的作用，并提供目标用于开发抗癌药物。他以前曾在癌症中心的许多职位任职包括领导乳腺癌计划以及最近的病因和化学预防领导者程序。他目前的个人研究兴趣以及培养合作的历史翻译研究使他成为领导该计划的理想候选人。作为该计划的领导者，古尔德博士正在重组重点，包括三个领域。第一个是哺乳动物和人类遗传学。该领域的核心目标是使用比较遗传学和基因组学更好地了解癌症的病因及其进展。这项工作以风险估计和预防癌症。第二个领域是统计遗传学和信息学。开发新的统计和信息方法来绘制测序基因组将是主要重点以及为复杂数据集开发独特的分析方法。第三个领域是物理基因组学这将开发出新的方法，以大规模获取癌症基因组学数据。古尔德博士通过组织面向任务的小组会议以及有限的大型小组会议和务虚会提供教育和探索机会潜在的协作策略。他还促进了介绍计划成员的教育研讨会向新的UWCCC共享资源和工具。他将培养既定的重要合作成员遗传学计划，化学预防计划与癌症控制计划之间的关系促进翻译进程媒介研究。古尔德博士为此致力于领导10％的努力程序。 Hasam Mukhtar博士曾担任化学预防计划的共同领导者。他收到了他的 1971年，印度坎普尔的坎普尔大学生物化学博士学位。他在博士后进行了博士后培训佐治亚州医学院对他对排毒酶的兴趣受到刺激。追求进一步在NIH的这一领域工作，他成为Case Western Reserve University的教职员工，并将代谢激活和排毒的专业知识，以探索调节癌变的方法。他的工作有现在扩展到饮食和癌症的研究，并关注饮食中的癌症化学预防。作为化学预防计划的共同领导者，Mukhtar博士将领导并刺激识别的努力具有化学预防功效的化合物，促进与转化科学家的合作行动机制和潜在目标机制，并与医生启动合作，以探索选择的选择化学预防的治疗策略。他将为这项活动投入5％的努力。道格拉斯·麦克尼尔（Douglas McNeel）博士将取代詹姆斯·斯图尔特（James Stewart）博士为实验治疗计划的共同领导者。麦克尼尔博士加入了威斯康星大学的教职员工，担任部门的助理教授医学于2001年7月。他于1986年在惠特曼学院获得化学和音乐学士学位。然后，他在芝加哥大学的医学科学家培训奖下进行研究生培训，并接受他的博士学位（生物化学和分子生物学）于1992年和1994年的医学博士。华盛顿大学的医学居住地在临床研究者途径和医疗 2000年，华盛顿大学和弗雷德·哈钦森癌症研究中心的肿瘤学奖学金。在临床研究金之后，他加入了华盛顿大学的肿瘤疫苗集团四年。在威斯康星大学，麦克尼尔博士继续专注于前列腺癌的免疫学。实验室研究旨在鉴定前列腺组织表达的蛋白质，这些蛋白质在淋巴细胞中识别前列腺癌和慢性炎症前列腺炎的患者，并鉴定疫苗策略能够诱导前列腺特异性炎症。临床研究探讨了免疫反应是否能够破坏前列腺癌细胞的前列腺癌患者可以通过疫苗。这项研究的远距离目标是开发用于前列腺辅助治疗的疫苗癌症。麦克尼尔博士被选为共同领导该计划，以解决显然缺乏计划的整合采用免疫治疗的成员与该计划的其余部分接触。他的临床研究活动的重点是前列腺癌和免疫学方法，特别是疫苗，用于治疗前列腺癌。他的实验室正在使用细胞和动物开发疫苗靶向前列腺酸性磷酸酶和雄激素受体的模型。他还领导临床试验在前列腺癌患者中评估这些方法。麦克尼尔博士将带来大量的基础科学和实验治疗计划的临床专业知识，并有助于整合重要的该计划的免疫学优势。他将为这项活动投入5％的努力。